| Related Articles |
Int J Radiat Oncol Biol Phys. 2020 Jan 30;:
Authors: van de Ven S, van den Bongard HJGD, Pielkenrood BJ, Kasperts N, Eppinga WSC, Peters M, Verkooijen HM, van der Velden JM
Abstract
PURPOSE: Stereotactic body radiotherapy (SBRT) has become a widely adopted treatment for patients with oligometastatic disease, despite limited evidence of superiority. We compared pain response and quality of life (QoL) in oligometastatic patients treated with conventionally fractionated 3D radiotherapy (3DCRT) or SBRT to bone metastases.
METHODS AND MATERIALS: We included patients with oligometastatic disease (≤5 lesions within ≤3 organs) treated within the prospective XXXX cohort. Main outcomes were pain response, clinical local control and quality of life (QoL) 2, 4, 8 weeks, 3, 6 and 12 months after treatment. Pain response was assessed only in patients who reported pain at baseline and defined according to international consensus criteria.
RESULTS: Of 131 patients with oligometastatic disease, 66 patients were treated with 3DCRT and 65 patients with SBRT. A pain response was achieved in 81% (3DCRT) versus 84% (SBRT) with a median duration of 23 weeks (range, 1-58) and 24 weeks (range, 0-50). Re-irradiation was needed in 33% versus 5% of the patients respectively. None of the QoL subscales were significantly different between both groups.
CONCLUSION: In oligometastatic patients, SBRT to bone metastases did not improve pain response or QoL compared to 3DCRT. Re-irradiation was less often needed in the SBRT group.
PMID: 32007565 [PubMed - as supplied by publisher]
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου